SCHEMBL17868800

SCHEMBL17868800

CCCCCCCCCCC(C)c1ccc(COCCOCCOCCOC)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 2/20 0.37
CYP3A4 P08684 2/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
CASP1 P29466 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SLCO1B3 Q9NPD5 1/20 0.35
SLCO1B1 Q9Y6L6 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.33
S1PR2 O95136 1/20 0.33
S1PR1 P21453 1/20 0.33
S1PR3 Q99500 1/20 0.33
LPAR2 Q9HBW0 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PLA2G4B P0C869 1/20 0.33
HTR1A P08908 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17027807 1.00 SLC2A1 (0.37) SLC2A1CYP3A4MEN1USP2ALDH1A1
SCHEMBL17027830 1.00 SLC2A1 (0.37) SLC2A1CYP3A4MEN1USP2ALDH1A1
SCHEMBL17027782 1.00 SLC2A1 (0.37) SLC2A1CYP3A4MEN1USP2ALDH1A1
SCHEMBL17868799 1.00 SLC2A1 (0.37) SLC2A1CYP3A4MEN1USP2ALDH1A1
SCHEMBL17027831 1.00 SLC2A1 (0.37) SLC2A1CYP3A4MEN1USP2ALDH1A1
SCHEMBL17868809 1.00 SLC2A1 (0.37) SLC2A1CYP3A4MEN1USP2ALDH1A1
SCHEMBL17027790 1.00 SLC2A1 (0.37) SLC2A1CYP3A4MEN1USP2ALDH1A1
SCHEMBL17027735 1.00 SLC2A1 (0.37) SLC2A1CYP3A4MEN1USP2ALDH1A1
SCHEMBL17027787 0.99 SLC2A1 (0.38) SLC2A1CYP3A4MEN1USP2ALDH1A1
SCHEMBL17027732 0.99 SLC2A1 (0.38) SLC2A1CYP3A4MEN1USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9758445-B2 Preparation of surfactants via cross-metathesis MATERIA, INC. (US) 2017-09-12 US disclosed
US-20160186094-A1 PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS MATERIA, INC. 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160186094-A1 PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS SMURF2, EPHX2, SMURF1 SLC2A1 2414/4885CYP3A4 398/4885MEN1 3213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.